By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boston Therapeutics, Inc. 

1750 Elm Street, Suite 103

Manchester  New Hampshire  03104  U.S.A.
Phone: 603-935-9799 Fax: 603-685-4784



Company News
Boston Therapeutics, Inc. Reports Topline U.S.-Based Phase 2b Study Results Of BTI-320 In Patients With Type 2 Diabetes 10/9/2014 8:01:18 AM
Boston Therapeutics, Inc. Appoints David S.H. Bell, MB, FACP, FACE To Its Medical Advisory Board 10/8/2014 9:36:16 AM
Boston Therapeutics, Inc. Files Patent Application For Novel Therapeutic Uses Of BTI-320 10/7/2014 10:22:15 AM
Boston Therapeutics, Inc. Appoints Jan Brinkman, M.D., Ph.D. And Alan M. Hoberman, Ph.D. To Board Of Directors 10/2/2014 10:53:56 AM
Benchworks Collaborates With Boston Therapeutics, Inc. To Market Sugardown® 9/29/2014 12:28:26 PM
Boston Therapeutics, Inc. Appoints Meng Hee Tan, M.D. To Consulting Medical Director 9/23/2014 11:34:24 AM
Boston Therapeutics, Inc. Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center For Phase III Study Of BTI-320 9/22/2014 11:12:01 AM
Boston Therapeutics, Inc. To Present Findings Of BTI-320 As Therapy For Glycemic Control At 50th Annual Meeting Of European Association For The Study Of Diabetes 9/17/2014 1:24:48 PM
Boston Therapeutics, Inc. To Present At National Investment Banking Conference On September 16, 2014 9/17/2014 1:07:14 PM
Boston Therapeutics, Inc. To Present At Rodman & Renshaw Annual Global Investment Conference On September 10, 2014 9/8/2014 12:36:12 PM